Literature DB >> 1280677

Angiogenic activity of fibrin degradation products is located in fibrin fragment E.

W D Thompson1, E B Smith, C M Stirk, F I Marshall, A J Stout, A Kocchar.   

Abstract

The source of angiogenic activity of fibrin degradation products has been sought in a series of experiments, applying degradation products from different types of fibrin and fibrinogen to the chick chorioallantoic membrane. The presence of platelets or fibronectin during clotting was not essential for activity, and neither was crosslinking. Fibrinogen degradation products were non-stimulatory, as was serum. Molecular sieve column chromatography indicated a range of active fragments. Admixture of active fibrin degradation products with antifibrin fragment E, but not D, antiserum neutralized activity. Preparations containing only fibrin fragment E retained activity. A commercial preparation of fibrinogen fragment E was inactive until treated with thrombin. These experiments point to fibrin fragment E being the source of angiogenic activity, with thrombin cleavage being the essential step in generating activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280677     DOI: 10.1002/path.1711680109

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  25 in total

Review 1.  Novel aspects of fibrin(ogen) fragments during inflammation.

Authors:  Carla Jennewein; Nguyen Tran; Patrick Paulus; Peter Ellinghaus; Johannes Andreas Eble; Kai Zacharowski
Journal:  Mol Med       Date:  2011-01-04       Impact factor: 6.354

Review 2.  Platelets: linking hemostasis and cancer.

Authors:  Shashank Jain; John Harris; Jerry Ware
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 3.  Embryonic angiogenesis: a review.

Authors:  J Wilting; B Christ
Journal:  Naturwissenschaften       Date:  1996-04

4.  Cardiac cell therapy: the next (re)generation.

Authors:  Elvira Forte; Isotta Chimenti; Lucio Barile; Roberto Gaetani; Francesco Angelini; Vittoria Ionta; Elisa Messina; Alessandro Giacomello
Journal:  Stem Cell Rev Rep       Date:  2011-11       Impact factor: 5.739

5.  High D-dimer levels are associated with poor prognosis in cancer patients.

Authors:  Cihan Ay; Daniela Dunkler; Robert Pirker; Johannes Thaler; Peter Quehenberger; Oswald Wagner; Christoph Zielinski; Ingrid Pabinger
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

Review 6.  The intertwined fates of inflammation and coagulation in glioma.

Authors:  Angela Cho; Kelly J McKelvey; Adrian Lee; Amanda L Hudson
Journal:  Mamm Genome       Date:  2018-07-30       Impact factor: 2.957

7.  D-dimer measured at first venous thromboembolism is associated with future risk of cancer.

Authors:  Olga V Gran; Sigrid K Brækkan; Benedikte Paulsen; Hanne Skille; John-Bjarne Hansen
Journal:  Haematologica       Date:  2016-09-09       Impact factor: 9.941

8.  Caveolin-1-dependent apoptosis induced by fibrin degradation products.

Authors:  Yi-He Guo; Irene Hernandez; Berend Isermann; Tae-bong Kang; Leonid Medved; Rashmi Sood; Edward J Kerschen; Trudy Holyst; Michael W Mosesson; Hartmut Weiler
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

9.  Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients.

Authors:  Andrea L Small-Howard; Holden Harris
Journal:  J Immunoassay Immunochem       Date:  2010

Review 10.  Injectable materials for the treatment of myocardial infarction and heart failure: the promise of decellularized matrices.

Authors:  Jennifer M Singelyn; Karen L Christman
Journal:  J Cardiovasc Transl Res       Date:  2010-07-15       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.